ライフサイエンスコーパス: early cancer

1 non-pedunculated rectal lesions (polyps and early cancers).

2 nded to detect high-grade dysplasia (HGD) or early cancer.

3 rrett's esophagus (BE) with dysplasia and/or early cancer.

4 radication treatment of BE with dysplasia or early cancer.

5 sed as sensitive biomarkers for diagnosis of early cancer.

6 to the diagnosis of treatable dysplasia and early cancer.

7 nagement of large flat colorectal polyps and early cancer.

8 to the development of novel tests to detect early cancers.

9 chitectures to characterize lung nodules and early cancers.

10 accuracy, identify tumor margins, and stage early cancers.

11 ing and surveillance is critical to identify early cancer after transplant.

12 rrett's esophagus (BE) with dysplasia and/or early cancer and appropriate follow-up of these patients

13 Tests that can detect both early cancer and cancer precursor lesions include sigmoi

14 invasive and may result in detection of both early cancer and cancer precursor lesions.

15 een shown to visualize capillary patterns in early cancer and is complementary to magnification endos

16 could prove vital for the identification of early cancer and people at risk of developing cancer.

17 ledge about how these screening tests detect early cancer and polyps and assess factors that influenc

18 aoperative imaging and enhanced detection of early cancers and metastases.

19 are being shown to enhance the detection of early cancers and precancerous lesions.

20 Early cancers are avascular and hence, profoundly acidic

21 ility to prevent recurrence in patients with early cancer at risk of metastasis.

22 The prospect of a widespread screening for early cancers, based on inexpensive point-of-care testin

23 e for the detection of l-lactate as a viable early cancer bio-marker.

24 sensing requirements and clinical needs for early cancer biomarker detection.

25 ta will be instrumental in identifying novel early cancer biomarkers and could provide a rationale fo

26 hnology platforms to facilitate detection of early cancer by means of biomarkers, and issues on the a

27 Because early cancers can be difficult to detect, our focus is o

28 Early cancer cell dissemination followed by a protracted

29 cer liver metastasis by enabling seeding and early cancer cell survival.

30 er2(+)p-p38(lo)p-Atf2(lo)Twist1(hi)E-cad(lo) early cancer cells that is invasive and can spread to ta

31 Finally, early cancer cells with NR2F1LOW/PRRX1HIGH staining were

32 to genome instability of precancerous and/or early cancer cells.

33 cient to generate at least two phenotypes of early cancer cells: genomic instability that involves mu

34 creening test that primarily is effective at early cancer detection and a screening test that is effe

35 d has favorable 5-year survival rates due to early cancer detection and availability of curative surg

36 duals can result in mortality reduction with early cancer detection and cancer prevention by detectio

37 d a screening test that is effective at both early cancer detection and cancer prevention through the

38 nt that has been clinically demonstrated for early cancer detection and guidance of therapy.

39 dvances the design of metabolic analysis for early cancer detection and holds promise as an efficient

40 ay highlights its potential to revolutionize early cancer detection and improve patient outcomes.

41 ly aid in screening prospective patients for early cancer detection and in monitoring the efficacy of

42 f tumor initiation has significant impact on early cancer detection and intervention.

43 ) health care system improvements to enhance early cancer detection and management to reduce reliance

44 sults indicate potential clinical benefit of early cancer detection and minimal patient distress asso

45 y discusses PLOS Medicine's Special Issue on early cancer detection and minimal residual disease.

46 r findings could form the basis for improved early cancer detection and monitoring in high-risk cance

47 oduct can potentially be used for screening, early cancer detection and patient stratification.

48 Early cancer detection and perfect understanding of the

49 solution, and identify candidate targets for early cancer detection and prevention.

50 C and patient survival time paves the way to early cancer detection and prognosis.

51 logy, with considerable potential to improve early cancer detection and risk assessment, and to enabl

52 tential to be applied in clinical diagnosis, early cancer detection and target identification for mol

53 Early cancer detection and treatment is an emerging and

54 oodstreams of cancer patients are pivotal to early cancer detection and treatment monitoring.

55 tic probe, this platform can pave the way to early cancer detection and treatment.

56 Surveillance and early cancer detection are associated with improved OS f

57 ty may hold greater diagnostic potential for early cancer detection as opposed to the identification

58 NAs as sensitive and specific biomarkers for early cancer detection as well as having demonstrated re

59 Early cancer detection by cell-free DNA faces multiple c

60 usion Use of a standalone AI system improved early cancer detection by correctly identifying some can

61 Early cancer detection can dramatically increase treatme

62 Noninvasive early cancer detection can potentially be achieved using

63 Early cancer detection currently relies on screening the

64 mework is a promising strategy for improving early cancer detection during a diagnostic process.

65 We first discuss early cancer detection enabled by nanodiscs.

66 fordable and accessible, ultimately enabling early cancer detection for a broader population.

67 Early cancer detection greatly increases the chances for

68 Early cancer detection has always been a major research

69 Improving early cancer detection has the potential to substantiall

70 Advances in imaging and early cancer detection have increased interest in magnet

71 detection of methylated ctDNA in plasma for early cancer detection in a clinical setting.

72 oscopy esophageal neoplasia (PEEN) undermine early cancer detection in Barrett's esophagus (BE).

73 oking cessation interventions, screening and early cancer detection in HIV-infected populations are o

74 ckade, further emphasizing the importance of early cancer detection in hosts that survive sepsis.

75 llows for personalized cancer prevention and early cancer detection in identified gene carriers.

76 auditing and targeted strategies to enhance early cancer detection in population screening.

77 al information that may improve contrast for early cancer detection in the gastrointestinal tract.

78 y introduce surveillance bias by influencing early cancer detection rates.

79 omarker and molecular imaging limitations of early cancer detection strategies and elucidates the del

80 a tumor-activatable MC to tumor cells for an early cancer detection strategy.

81 nomaterials on the accuracy of biosensors in early cancer detection such as lung, prostate, breast, a

82 This opens the possibility to develop an early cancer detection test based on a set of peptide se

83 Patient survival increased due to early cancer detection that results in increased probabi

84 tile properties with nano-biosensors towards early cancer detection to preserve human health.

85 Thus early cancer detection via PPi recognition in physiologi

86 band imaging have a 77-99.4% sensitivity for early cancer detection, a significant improvement when c

87 ART access, early cancer detection, and improved cancer treatment ar

88 ulating nucleic acids in prenatal diagnosis, early cancer detection, and the diagnosis of infectious

89 port applications in rare variant detection, early cancer detection, and therapy selection with reduc

90 edical applications including ophthalmology, early cancer detection, and understanding fundamental di

91 free DNA (cfDNA) could enable more sensitive early cancer detection, but it is technologically challe

92 loser to the clinic where it can be used for early cancer detection, disease characterization and gui

93 ng as one of the diagnostic frontrunners for early cancer detection, disease monitoring, and treatmen

94 binations has the potential to revolutionize early cancer detection, especially for cancers with no a

95 RG variants are potentially useful to aid in early cancer detection, immediate patient risk stratific

96 led to the implementation in the clinic for early cancer detection, improved cancer staging, early d

97 w-proportion tumor subclones can be used for early cancer detection, prognostic assessment and therap

98 cians (PCPs) are significant contributors of early cancer detection, yet few studies have investigate

99 ical samples hold great promise for reliable early cancer detection.

100 developed to quantify nuclear morphology for early cancer detection.

101 evelopment of noninvasive clinical tests for early cancer detection.

102 rker discovery and provide new insights into early cancer detection.

103 ctrometry is a potentially powerful tool for early cancer detection.

104 gery with a slight compromise in the rate of early cancer detection.

105 e applications, such as enzyme discovery and early cancer detection.

106 biofluids and have shown great potential for early cancer detection.

107 inimal residual disease (MRD) monitoring and early cancer detection.

108 be leveraged as non-invasive biomarkers for early cancer detection.

109 light possible trajectories for the field of early cancer detection.

110 of EVs and the rationale for using them for early cancer detection.

111 t-effective, and widely accessible tools for early cancer detection.

112 mance of diagnostic assays, particularly for early cancer detection.

113 ancer samples, a significant step forward in early cancer detection.

114 or subtypes, thus holding a great promise in early cancer detection.

115 crobiome using liquid biopsies could improve early cancer detection.

116 indings establish the potential for sEVA for early cancer detection.

117 sies are considered a screening approach for early cancer detection.

118 d cancer therapy options, and guidelines for early cancer detection.

119 use as a readily available liquid biopsy for early cancer detection.

120 rkers from a noninvasive liquid bioassay for early cancer detection.

121 and will shape the future AI development in early cancer detection.

122 unclear whether bulk measurements will allow early cancer detection.

123 why these technologies will be necessary for early cancer detection.

124 radiologists in interpreting mammograms for early cancer detection.

125 ll-based in vivo sensor for highly sensitive early cancer detection.

126 uppressor genes is a promising biomarker for early cancer detection.

127 dentification of low frequency mutations for early cancer detection.

128 r harnessing the humoral immune response for early cancer detection.

129 tages of cancer, with promising findings for early cancer detection.

130 s of cancer, and highlight opportunities for early cancer detection.

131 Identification of early cancer, detection of progression, and monitoring o

132 thelial cell apical-basal polarity occurs in early cancer development and is often correlated with in

133 The role of adaptive immunity in early cancer development is controversial.

134 window of opportunity" for intervention when early cancer development may be observable.

135 n of cancer genes and occur predominantly in early cancer development rather than the later stages of

136 Despite its potential importance in early cancer development, the precise nature of oncogene

137 ed in normal tissue, and two associated with early cancer development.

138 unknown, precluding important insights into early cancer development.

139 lated by hormonal pathways that might affect early cancer development.

140 s in promoter regions acts as a precursor to early cancer development.

141 differentiation and CD11b(+)Ly6G(+) IMCs in early cancer development.

142 sy") offers great prospects for non-invasive early cancer diagnosis and clinical guidance, but requir

143 NAs) have emerged as critical biomarkers for early cancer diagnosis and monitoring.

144 ion of low-frequency mutations, facilitating early cancer diagnosis and personalized treatment strate

145 oRNAs are extremely promising candidates for early cancer diagnosis and prognosis.

146 e availability of the reviewed platforms for early cancer diagnosis and the approval of methylation i

147 IR-fluorescence enhancement microarrays, for early cancer diagnosis and therapeutic monitoring.

148 icularly in the context of liquid biopsy for early cancer diagnosis and treatment.

149 ancy and that early recognition is vital for early cancer diagnosis and treatment.

150 bundant DNA point mutations is essential for early cancer diagnosis and/or prognosis.

151 se genes could provide a powerful method for early cancer diagnosis as well as insight into mechanism

152 related autoantibodies provides a means for early cancer diagnosis as well as leads for therapy.

153 eloped in this work show its suitability for early cancer diagnosis based on miRNA as a biomarker.

154 RNAs in biomedical field with an emphasis on early cancer diagnosis by overviewing both research base

155 ndance methylation is a crucial challenge in early cancer diagnosis in a simple manner.

156 Early cancer diagnosis is critical for improving patient

157 Early cancer diagnosis is critical for the prevention of

158 Early cancer diagnosis is of prime importance as it pave

159 ial to detect rare DNA-sequence variants for early cancer diagnosis or drug-resistance mutation ident

160 Non-invasive early cancer diagnosis remains challenging due to the lo

161 Early cancer diagnosis remains the holy-grail in the bat

162 ne (considered as an excellent biomarker for early cancer diagnosis) with a detection limit of 66 ppb

163 cellular therapeutic modalities, preclinical early cancer diagnosis, and a novel approach in immunoth

164 fDNA) assay would be a promising approach to early cancer diagnosis, especially for patients with den

165 methylation detection via liquid biopsy for early cancer diagnosis, improvements in the sensitivity

166 associated molecules could be beneficial for early cancer diagnosis, monitoring and surveillance.

167 s great promise for its translational use in early cancer diagnosis, prognostic assessment of tumor b

168 rculating miRNA-21, a reliable biomarker for early cancer diagnosis.

169 esicles (EVs) hold promise as biomarkers for early cancer diagnosis.

170 care utilisation, offering opportunities for early cancer diagnosis.

171 and is likely to have great significance in early cancer diagnosis.

172 methylation, which is closely correlated to early cancer diagnosis.

173 improved public health monitoring and aid in early cancer diagnosis.

174 his AI-based approach may be used for "Super Early" cancer diagnosis and amend the current immunother

175 This complex represents a potentially new early cancer diagnostic for detecting deficiencies in mi

176 ancer cells/tissues have great potential for early cancer diagnostic use, but their clinical potentia

177 ipment, which would offer a new platform for early cancer diagnostics, especially in those resource-l

178 considered as an important tumor marker for early cancer diagnostics.

179 lude that MT1-MMP plays an important role in early cancer dissemination by converting epithelial cell

180 asion, survival/death, and stemness, promote early cancer dissemination.

181 sed mutagenesis allows the identification of early cancer drivers, but current sequencing methods hav

182 The signature of early cancer dynamics on the spatial arrangement of tumo

183 sub-clonal mixing can provide insights into early cancer dynamics.

184 ents with Barrett esophagus and dysplasia or early cancer, endoscopic therapy consisting of resection

185 ntribution of transcriptional variability to early cancer evolution reflects a generic role in promot

186 croenvironmental and tissue-level factors in early cancer evolution.

187 anoids indicated the presence of an aberrant early cancer gene signature, which clustered with the he

188 ties of filter inference using examples from early cancer growth modelling and from epidermal growth

189 ning in at-risk populations and detection of early cancer has the potential to significantly alter su

190 The early cancer-immune interaction sculpts intratumor heter

191 ntigen receptors (CAR) have shown promise in early cancer immunotherapy clinical trials.

192 py is frequently used to treat dysplasia and early cancers in Barrett's esophagus.

193 of MRI to identify potential precancerous or early cancers in individuals at risk for pancreatic canc

194 submucosal dissection to treat dysplasia and early cancers in the luminal gastrointestinal tract.

195 logy and techniques, the future treatment of early cancers in the upper gastrointestinal tract may be

196 Tests that primarily detect early cancer include sensitive guaiac fecal occult blood

197 However, the specific induction of early cancer-initiating mutations within differentiated

198 the potential to unveil novel biomarkers of early cancer initiation.

199 ithelial AR serves as a tumour suppressor in early cancer initiation.

200 Finally, we consider existing strategies for early cancer interception with perspectives on the next

201 the pretest probability that a biomarker of early cancer is a true positive and warrants further inv

202 The most significant development for staging early cancers is mucosal resection.

203 te stages, and that the genomic landscape of early cancers is not representative of that of lethal ca

204 rs, suggesting potential novel candidates on early cancer medicine.

205 s of anoscopy, which diagnoses some cases of early cancer; nevertheless, sensitivity of this test ran

206 a histologic marker in the identification of early cancer of the gastric stump.

207 copic mucosal resection (EMR) of superficial early cancers of the upper gastrointestinal tract is sta

208 endoscopic mucosal resection of superficial early cancers of the upper gastrointestinal tract.

209 issues reflective of low malignant potential/early cancer onset and possible pre-cancerous stages inv

210 r phenotype groups with differential risk of early cancer onset as well as lifetime risk of cancer.

211 ssues reflective of low potential malignancy/early cancer onset stages via long distance signaling be

212 circulating extracellular vesicles (EV) from early cancers or different types of host cells requires

213 nctures, including diagnosis, treatment, and early cancer outcome.

214 sting that these acinar regions represent an early cancer precursor lesion.

215 Bloom syndrome is a disorder of profound and early cancer predisposition in which cells become hyperm

216 circulating metabolites are associated with early cancer progression is unknown.

217 l cellular dynamics, providing insights into early cancer progression.

218 ng to their different metabolomes to predict early cancer recurrence.

219 from patients with shorter survival time or early cancer recurrence.

220 ing of post-treatment NPC patients to detect early cancer recurrences in the head and neck.

221 BC high-risk patients and detect evidence of early cancer-related genomic lesions.

222 Non-invasive assays for early cancer screening are hampered by challenges in the

223 However, the option for early cancer screening is limited, with most cancer type

224 Early cancer screening is needed for timely clinical int

225 l translational potentials as biomarkers for early cancer screening, diagnostic and/or therapeutic in

226 cally difficult to use as a routine tool for early cancer screening.

227 metabolic data, can be effectively used for early cancer screening.

228 ce to health care, which may be a barrier to early cancer screening.

229 Median cancer size and the percentage of early cancers showed little change with any factors.

230 pecific outcomes (eg, recurrence pattern and early cancer-specific mortality) were determined.

231 common, and more patients were diagnosed at early cancer stage.

232 performed by jail and prison nursing staff, early cancer symptoms are often missed altogether or mis

233 the biology and trajectory of precancer and early cancer to identify consequential disease that requ

234 subjects at high risk for cancer, to detect early cancer, to detect the early recurrence of establis

235 s a potential tumor-suppressive mechanism in early cancer transitions.

236 noninvasive repeatable biomarkers to detect early cancer treatment response and spare non-responders

237 nobiosensors are to explore the efficacy for early cancer tumour detection or single molecular detect

238 Clinically relevant precursors and early cancers were too small to be detected.Keywords: Ge

239 at multiple stages of gastric dysplasia and early cancer with FA supplementation initiated both at w

240 y, which allows gastroenterologists to treat early cancers with greater confidence regarding rates of